Last reviewed · How we verify
DYMISTA nasal spray
DYMISTA is a nasal spray combining azelastine (a selective H1-receptor antagonist) and fluticasone propionate (a corticosteroid) to reduce allergic rhinitis symptoms through dual anti-inflammatory and antihistamine action.
DYMISTA is a nasal spray combining azelastine (a selective H1-receptor antagonist) and fluticasone propionate (a corticosteroid) to reduce allergic rhinitis symptoms through dual anti-inflammatory and antihistamine action. Used for Allergic rhinitis (seasonal and perennial).
At a glance
| Generic name | DYMISTA nasal spray |
|---|---|
| Sponsor | Glenmark Pharmaceuticals Ltd. India |
| Drug class | Antihistamine/Intranasal corticosteroid combination |
| Target | H1 receptor (azelastine); Glucocorticoid receptor (fluticasone propionate) |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | Phase 3 |
Mechanism of action
Azelastine blocks histamine H1 receptors to provide rapid symptom relief from itching, sneezing, and rhinorrhea, while fluticasone propionate reduces nasal inflammation and mucus production through glucocorticoid receptor activation. The combination provides both immediate antihistamine relief and sustained anti-inflammatory control of allergic rhinitis.
Approved indications
- Allergic rhinitis (seasonal and perennial)
Common side effects
- Headache
- Epistaxis (nosebleed)
- Nasal irritation
- Dysgeusia (taste disturbance)
- Somnolence
Key clinical trials
- Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis (PHASE4)
- Patient Satisfaction and Sensory Attributes Allergic Rhinitis Nasal Spray
- Bioequivalence Study of Azelastine Hydrochloride/ Fluticasone Propionate 137 Microgram/50 Microgram Nasal Spray and Dymista Nasal Spray (PHASE1)
- Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients
- Allergic Rhinitis Combination Pharmacotherapy Efficacy Study (PHASE4)
- A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergic Rhinitis (PHASE2)
- Dymista Allergen Chamber - Onset of Action Study (PHASE4)
- DYmista NAsal Spray in CHInese Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |